103 research outputs found
Catheter-based intramyocardial injection of FGF1 or NRG1-loaded MPs improves cardiac function in a preclinical model of ischemia-reperfusion
Cardiovascular protein therapeutics such as neuregulin (NRG1) and acidic-fibroblast growth factor
(FGF1) requires new formulation strategies that allow for sustained bioavailability of the drug in the
infarcted myocardium. However, there is no FDA-approved injectable protein delivery platform due
to translational concerns about biomaterial administration through cardiac catheters. We therefore
sought to evaluate the efficacy of percutaneous intramyocardial injection of poly(lactic-co-glycolic
acid) microparticles (MPs) loaded with NRG1 and FGF1 using the NOGA MYOSTAR injection catheter
in a porcine model of ischemia-reperfusion. NRG1- and FGF1-loaded MPs were prepared using a
multiple emulsion solvent-evaporation technique. Infarcted pigs were treated one week after ischemiareperfusion
with MPs containing NRG1, FGF1 or non-loaded MPs delivered via clinically-translatable
percutaneous transendocardial-injection. Three months post-treatment, echocardiography indicated
a significant improvement in systolic and diastolic cardiac function. Moreover, improvement in bipolar
voltage and decrease in transmural infarct progression was demonstrated by electromechanical
NOGA-mapping. Functional benefit was associated with an increase in myocardial vascularization
and remodeling. These findings in a large animal model of ischemia-reperfusion demonstrate the
feasibility and efficacy of using MPs as a delivery system for growth factors and provide strong evidence
to move forward with clinical studies using therapeutic proteins combined with catheter-compatible
biomaterials
Selective Induction of DNA Repair Pathways in Human B Cells Activated by CD4+ T Cells
Greater than 75% of all hematologic malignancies derive from germinal center (GC) or post-GC B cells, suggesting that the GC reaction predisposes B cells to tumorigenesis. Because GC B cells acquire expression of the highly mutagenic enzyme activation-induced cytidine deaminase (AID), GC B cells may require additional DNA repair capacity. The goal of this study was to investigate whether normal human B cells acquire enhanced expression of DNA repair factors upon AID induction. We first demonstrated that several DNA mismatch repair, homologous recombination, base excision repair, and ATR signaling genes were overexpressed in GC B cells relative to naïve and memory B cells, reflecting activation of a process we have termed somatic hyperrepair (SHR). Using an in vitro system, we next characterized activation signals required to induce AID expression and SHR. Although AID expression was induced by a variety of polyclonal activators, SHR induction strictly required signals provided by contact with activated CD4+ T cells, and B cells activated in this manner displayed reduced levels of DNA damage-induced apoptosis. We further show the induction of SHR is independent of AID expression, as GC B cells from AID -/- mice retained heightened expression of SHR proteins. In consideration of the critical role that CD4+ T cells play in inducing the SHR process, our data suggest a novel role for CD4+ T cells in the tumor suppression of GC/post-GC B cells
Acetylation of the Pro-Apoptotic Factor, p53 in the Hippocampus following Cerebral Ischemia and Modulation by Estrogen
Recent studies demonstrate that acetylation of the transcription factor, p53 on lysine(373) leads to its enhanced stabilization/activity and increased susceptibility of cells to stress. However, it is not known whether acetylation of p53 is altered in the hippocampus following global cerebral ischemia (GCI) or is regulated by the hormone, 17β-estradiol (17β-E(2)), and thus, this study examined these issues.The study revealed that Acetyl p53-Lysine(373) levels were markedly increased in the hippocampal CA1 region after GCI at 3 h, 6 h and 24 h after reperfusion, an effect strongly attenuated by 17β-E(2). 17β-E(2) also enhanced interaction of p53 with the ubiquitin ligase, Mdm2, increased ubiquitination of p53, and induced its down-regulation, as well as attenuated elevation of the p53 transcriptional target, Puma. We also observed enhanced acetylation of p53 at a different lysine (Lys(382)) at 3 h after reperfusion, and 17β-E(2) also markedly attenuated this effect. Furthermore, administration of an inhibitor of CBP/p300 acetyltransferase, which acetylates p53, was strongly neuroprotective of the CA1 region following GCI. In long-term estrogen deprived (LTED) animals, the ability of 17β-E(2) to attenuate p53 acetylation was lost, and intriguingly, Acetyl p53-Lysine(373) levels were markedly elevated in sham (non-ischemic) LTED animals. Finally, intracerebroventricular injections of Gp91ds-Tat, a specific NADPH oxidase (NOX2) inhibitor, but not the scrambled tat peptide control (Sc-Tat), attenuated acetylation of p53 and reduced levels of Puma following GCI.The studies demonstrate that p53 undergoes enhanced acetylation in the hippocampal CA1 region following global cerebral ischemia, and that the neuroprotective agent, 17β-E(2), markedly attenuates the ischemia-induced p53 acetylation. Furthermore, following LTED, the suppressive effect of 17β-E(2) on p53 acetylation is lost, and p53 acetylation increases in the hippocampus, which may explain previous reports of increased sensitivity of the hippocampus to ischemic stress following LTED
Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations
BACKGROUND: Progressive supranuclear palsy (PSP) -Richardson's Syndrome and Corticobasal Syndrome (CBS) are the two classic clinical syndromes associated with underlying four repeat (4R) tau pathology. The PSP Rating Scale is a commonly used assessment in PSP clinical trials; there is an increasing interest in designing combined 4R tauopathy clinical trials involving both CBS and PSP. OBJECTIVES: To determine contributions of each domain of the PSP Rating Scale to overall severity and characterize the probable sequence of clinical progression of PSP as compared to CBS. METHODS: Multicenter clinical trial and natural history study data were analyzed from 545 patients with PSP and 49 with CBS. Proportional odds models were applied to model normalized cross-sectional PSP Rating Scale, estimating the probability that a patient would experience impairment in each domain using the PSP Rating Scale total score as the index of overall disease severity. RESULTS: The earliest symptom domain to demonstrate impairment in PSP patients was most likely to be Ocular Motor, followed jointly by Gait/Midline and Daily Activities, then Limb Motor and Mentation, and finally Bulbar. For CBS, Limb Motor manifested first and ocular showed less probability of impairment throughout the disease spectrum. An online tool to visualize predicted disease progression was developed to predict relative disability on each subscale per overall disease severity. CONCLUSION: The PSP Rating Scale captures disease severity in both PSP and CBS. Modelling how domains change in relation to one other at varying disease severities may facilitate detection of therapeutic effects in future clinical trials
A922 Sequential measurement of 1 hour creatinine clearance (1-CRCL) in critically ill patients at risk of acute kidney injury (AKI)
Meeting abstrac
Catheter-based intramyocardial injection of FGF1 or NRG1-loaded MPs improves cardiac function in a preclinical model of ischemia-reperfusion
Cardiovascular protein therapeutics such as neuregulin (NRG1) and acidic-fibroblast growth factor
(FGF1) requires new formulation strategies that allow for sustained bioavailability of the drug in the
infarcted myocardium. However, there is no FDA-approved injectable protein delivery platform due
to translational concerns about biomaterial administration through cardiac catheters. We therefore
sought to evaluate the efficacy of percutaneous intramyocardial injection of poly(lactic-co-glycolic
acid) microparticles (MPs) loaded with NRG1 and FGF1 using the NOGA MYOSTAR injection catheter
in a porcine model of ischemia-reperfusion. NRG1- and FGF1-loaded MPs were prepared using a
multiple emulsion solvent-evaporation technique. Infarcted pigs were treated one week after ischemiareperfusion
with MPs containing NRG1, FGF1 or non-loaded MPs delivered via clinically-translatable
percutaneous transendocardial-injection. Three months post-treatment, echocardiography indicated
a significant improvement in systolic and diastolic cardiac function. Moreover, improvement in bipolar
voltage and decrease in transmural infarct progression was demonstrated by electromechanical
NOGA-mapping. Functional benefit was associated with an increase in myocardial vascularization
and remodeling. These findings in a large animal model of ischemia-reperfusion demonstrate the
feasibility and efficacy of using MPs as a delivery system for growth factors and provide strong evidence
to move forward with clinical studies using therapeutic proteins combined with catheter-compatible
biomaterials
Combined catheter ablation and left atrial appendage closure as a hybrid procedure for the treatment of atrial fibrillation
Aims: Left atrial appendage (LAA) is the source of thrombi in up to 90% of patients with non-valvular atrial fibrillation (AF). Catheter ablation (CA) is an effective treatment for symptomatic AF and, in selected cases, LAA occlusion devices have been introduced as an alternative to oral anticoagulants (OACs). The safety and feasibility of combining CA and percutaneous LAA closure (LAAC) are unknown.
Methods and results: Patients with symptomatic drug-refractory AF, CHADS2 score of ≥1, and CHA2DS2-VASc score ≥2 were included. Catheter ablation consisted in pulmonary vein isolation with or without roof line with radiofrequency and LAA was occluded with the Watchman or Amplatzer Cardiac Plug (ACP) devices guided by angiography and transoesophageal echocardiography. A total of 35 patients were included (71% male; 70 years). Median score was 3 on both CHA2DS2-VASc and HAS-BLED, 9% had prior stroke under OAC, and 48% had bleeding complications. Successful CA and device implantation were achieved in 97% of cases. The Watchman device was used in 29 patients and ACP in 6 patients. Periprocedural complications included three cases of cardiac tamponade. At 3 months, all patients met the criteria for successful sealing of the LAA. After a mean follow-up of 13 months (3-75), 78% of patients were free of arrhythmia recurrences and OAC was withheld in 97% of patients.
Conclusions: The combination of CA and percutaneous LAAC in a single procedure is technically feasible in patients with symptomatic drug-refractory AF, high risk of stroke, and contraindications to OACs, although it is associated with a significant risk of major complications
- …